Morten Ladekarl

18PUBLICATIONS
57CO-AUTHORS
Nanotoxicology, health and safetyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersNeurology and neuromuscular diseasesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Apr 20, 2026
Safety of [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT including hemodynamic measurements and patient-reported outcomes in cancer patients.

|Mar 30, 2026
Efficacy of FOLFIRINOX in digestive neuroendocrine carcinoma.

B P Butt, H Sorbye, M Ladekarl

|Feb 26, 2026
Characteristics, Prognosis and Reasons for Opting-Out of Treatment in Patients with Untreated Pancreatic Cancer.

Morten Ladekarl, Mogens Tornby Stender

|Feb 05, 2026
Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.

Siren Morken, Seppo W Langer, Geir Olav Hjortland

|Jan 12, 2026
Characteristics, treatment, and outcome of recurrent gastro-oesophageal adeno-carcinoma after perioperative chemotherapy and radical resection.

Anders Christian Larsen, Susy Shim, Lene Bæksgaard

|Sep 19, 2025
The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST.

Mette M Steiniche, Sidsel C Lindgaard, Inna M Chen

Pageof 3

Frequent Collaborators

4 joint publications

Siren Morken

4 joint publications

Halfdan Sorbye

3 joint publications

Mette T Mouritzen

3 joint publications

Andreas Carus